Celgene Strikes $78M Deal In Elan Abraxane IP Suit
Elan Pharma International Ltd. and Celgene Corp. announced a $78 million settlement Thursday that ends four years of litigation over breast cancer drug Abraxane, which allegedly infringed two patents held by...To view the full article, register now.
Already a subscriber? Click here to view full article